

**West Midlands Cancer Alliance (WMCA) Collaboration:
Optimising the Specialist Skin Cancer MDT pathway.**

Summary of Collaborative Working Project	The opportunity for the collaborative working programme has been facilitated through the Midlands Life Sciences Partnership Hub as part of their role in supporting NHS-industry collaboration across agreed cancer pathway challenges and they will provide oversight of the programme. The work will be delivered through the West Midlands Cancer Alliance (WMCA) and the WMCA region. The collaborative working programme with Regeneron and West Midlands Cancer Alliance aims to co-develop and implement standardised processes to improve the efficiency of the skin cancer MDT pathways within the hospitals in the West Midlands Cancer Alliance Region. The outputs and learnings aim develop a case study / learning summary for use by WMCA, the Life Science Hub and participating hospitals, subject to appropriate review and approvals.
The organisations involved	West Midlands Cancer Alliance (WMCA) Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton Rd, Heath Town, Wolverhampton, WV10 0QP. Midlands Life Science Partnership Hub (LSH) Level 3, Balmoral Building, Leicester Royal Infirmary, Infirmary Square, Leicester, Leicestershire, LE1 5WW Regeneron The Charter Building, Vine Street, Uxbridge, Middlesex, UB8 1JG
Objectives of the Project	Building on the WMCA Quality Assurance assessments of regional skin cancer MDTs, the programme will prioritise MDTs requiring project management support from a Quality Assurance review of MDT's undertaken by the WMCA. The programme will then implement standardised MDT processes, and equip hospital teams to embed and sustain these improvements to optimise MDT performance and share examples of best practice across the region. The skin cancer Hospital MDT's from the region that are able to be part of this programme with their agreement are as follows: University Hospitals of Coventry and Warwickshire NHS Trust The Royal Wolverhampton NHS Trust University Hospitals of North Midlands NHS Trust The Shrewsbury and Telford Hospital NHS Trust The Dudley Group NHS Foundation Trust The Royal Wolverhampton NHS Trust Sandwell and West Birmingham Hospitals NHS Trust Walsall Healthcare NHS Trust Worcestershire Acute Hospitals NHS Trust Wye Valley NHS Trust South Warwickshire NHS Foundation Trust George Elliot Hospital NHS Trust
Expected outcomes	<u>Patients</u> - Reduction in delays, leading to more efficient communication to patients from the MDT, and therefore an opportunity to support patients along the process. - Earlier communication of a treatment plan, due to a more efficient MDT process. - Improved patient outcomes <u>West Midlands Cancer Alliance and Hospitals where optimisation is delivered</u> - Potential improvement in use of limited staff resources when supporting the MDT process.

	- Improvements in staff satisfaction. - Enhance quality of service. - Improve cancer waiting times performance. - Shared learning across the Cancer Alliance. <u>Regeneron</u> - Building a collaborative working relationship with the NHS - Showing evidence of expertise and offering to support optimal care for patients. - May provide improved access to treatments in line with NICE guidance which may or may not include Regeneron medicines.
Time Frame	August 2026 – December 2026